PR Newswire BiotechOriginal article
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million
Positive
AI Analysis
Summary
A federal jury in Delaware found Avilar Therapeutics and RA Capital willfully and maliciously misappropriated a trade secret developed at Yale, awarding Biohaven and Yale University $4 million in damages.
Outcome Details
Federal jury verdict in favor of Biohaven and Yale University; defendants found to have willfully and maliciously misappropriated trade secret developed at Yale; $4 million awarded
Importance:6/10
Sentiment:
0.80
litigationintellectual propertytrade secret misappropriationjury verdictdamages awarded
Related Companies
Read the original article
Published by PR Newswire Biotech on July 27, 2026 11:00 AM